ARX788 in Selected HER2-mutated or HER2-amplified Solid Tumors (ACE-Pan Tumor-02)

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified Solid Tumors (ACE-Pan tumor-02)

Phase 2

Ambrx, Inc.